Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Assenat

Showing results (101-110 of 153) with videos related to

Pageof 16
Sort By:
British Journal of Cancer|June 3, 2021
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpressionThomas Decaens, Carlo Barone, Eric Assenat, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 14, 2024
Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohortMatthieu Delaye, Alice Boilève, Julie Henriques, et al.
Oncotarget|April 29, 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialEric Assenat, David Azria, Caroline Mollevi, et al.
Journal of Hepatology|January 30, 2017
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCCRiccardo Lencioni, Robert Montal, Ferran Torres, et al.
British Journal of Cancer|April 7, 2021
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpressionThomas Decaens, Carlo Barone, Eric Assenat, et al.
Cancers|July 2, 2021
Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective StudyThibault Mazard, Laure Cayrefourcq, Françoise Perriard, et al.
Journal of Hepatology|May 7, 2014
Characterization of a novel PXR isoform with potential dominant-negative propertiesCyril Breuker, Chris Planque, Fatemeh Rajabi, et al.
Radiology|May 1, 2019
Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II TrialBoris Guiu, Patrick Chevallier, Eric Assenat, et al.
Therapeutic Advances in Medical Oncology|November 20, 2024
SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumorsPascal Hammel, Denis Smith, Pauline Afchain, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 2, 2025
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY DataHéloïse Bourien, Xavier Adhoute, Boris Campillo-Gimenez, et al.
Pageof 16

Showing results (101-110 of 153) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|June 3, 2021
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpressionThomas Decaens, Carlo Barone, Eric Assenat, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 14, 2024
Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohortMatthieu Delaye, Alice Boilève, Julie Henriques, et al.
Oncotarget|April 29, 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialEric Assenat, David Azria, Caroline Mollevi, et al.
Journal of Hepatology|January 30, 2017
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCCRiccardo Lencioni, Robert Montal, Ferran Torres, et al.
British Journal of Cancer|April 7, 2021
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpressionThomas Decaens, Carlo Barone, Eric Assenat, et al.
Cancers|July 2, 2021
Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective StudyThibault Mazard, Laure Cayrefourcq, Françoise Perriard, et al.
Journal of Hepatology|May 7, 2014
Characterization of a novel PXR isoform with potential dominant-negative propertiesCyril Breuker, Chris Planque, Fatemeh Rajabi, et al.
Radiology|May 1, 2019
Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II TrialBoris Guiu, Patrick Chevallier, Eric Assenat, et al.
Therapeutic Advances in Medical Oncology|November 20, 2024
SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumorsPascal Hammel, Denis Smith, Pauline Afchain, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 2, 2025
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY DataHéloïse Bourien, Xavier Adhoute, Boris Campillo-Gimenez, et al.
Pageof 16